PHASE II STUDY OF PEMBROLIZUMAB PLUS SURVAXM FOR GLIOBLASTOMA AT FIRST RECURRENCE

被引：0

作者：

Ahluwalia, Manmeet ^{[1
]}

Peereboom, David ^{[1
]}

Rauf, Yasmeen ^{[2
]}

Schilero, Cathy ^{[1
]}

Ciolfi, Marci ^{[1
]}

Ciesielski, Michael ^{[3
]}

Fenstermaker, Robert ^{[4
]}

机构：

[1] Cleveland Clin, Main Campus, Cleveland, OH 44106 USA

[2] Cleveland Clin, Dublin, OH USA

[3] Roswell Pk, Buffalo, NY USA

[4] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

来源：

NEURO-ONCOLOGY | 2020年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CTIM-10

引用

页码：34 / 35

页数：3

共 50 条

[41] Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Nassiri, Farshad
Patil, Vikas
Yefet, Leeor S.
Singh, Olivia
Liu, Jeff
Dang, Rachel M. A.
Yamaguchi, Takafumi N.
Daras, Mariza
Cloughesy, Timothy F.
Colman, Howard
Kumthekar, Priya U.
Chen, Clark C.
Aiken, Robert
Groves, Morris D.
Ong, Shirley S.
Ramakrishna, Rohan
Vogelbaum, Michael A.
Khagi, Simon
Kaley, Thomas
Melear, Jason M.
Peereboom, David M.
Rodriguez, Analiz
Yankelevich, Maxim
Nair, Suresh G.
Puduvalli, Vinay K.
Aldape, Kenneth
Gao, Andrew
Lopez-Janeiro, Alvaro
de Andrea, Carlos E.
Alonso, Marta M.
Boutros, Paul
Robbins, Joan
Mason, Warren P.
Sonabend, Adam M.
Stupp, Roger
Fueyo, Juan
Gomez-Manzano, Candelaria
Lang, Frederick F.
Zadeh, Gelareh
NATURE MEDICINE, 2023, 29 (06) : 1370 - +
[42] Pembrolizumab plus docetaxel for the treatment of recurrent metastatic head and neck cancer: A prospective phase I/II study
Fuereder, T.
Minichsdorfer, C.
Mittlboeck, M.
Wagner, C.
Oberndorfer, F.
Mullauer, L.
Aretin, M-B.
Czerny, C.
Schwarz-Nemec, U.
ANNALS OF ONCOLOGY, 2020, 31 : S665 - S665
[43] Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Farshad Nassiri
Vikas Patil
Leeor S. Yefet
Olivia Singh
Jeff Liu
Rachel M. A. Dang
Takafumi N. Yamaguchi
Mariza Daras
Timothy F. Cloughesy
Howard Colman
Priya U. Kumthekar
Clark C. Chen
Robert Aiken
Morris D. Groves
Shirley S. Ong
Rohan Ramakrishna
Michael A. Vogelbaum
Simon Khagi
Thomas Kaley
Jason M. Melear
David M. Peereboom
Analiz Rodriguez
Maxim Yankelevich
Suresh G. Nair
Vinay K. Puduvalli
Kenneth Aldape
Andrew Gao
Álvaro López-Janeiro
Carlos E. de Andrea
Marta M. Alonso
Paul Boutros
Joan Robbins
Warren P. Mason
Adam M. Sonabend
Roger Stupp
Juan Fueyo
Candelaria Gomez-Manzano
Frederick F. Lang
Gelareh Zadeh
Nature Medicine, 2023, 29 : 1370 - 1378
[44] ONCOLYTIC DNX-2401 VIROTHERAPY PLUS PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA: A PHASE 1/2 TRIAL
Nassiri, Farshad
Patil, Vikas
Yefet, Leeor
Singh, Olivia
Liu, Jeff
Dang, Rachel
Yamaguchi, Takafumi
Daras, Mariza
Cloughesy, Timothy
Colman, Howard
Kumthekar, Priya
Chen, Clark
Aiken, Robert
Groves, Morris
Ong, Shirley
Ramakrishna, Rohan
Vogelbaum, Michael A.
Khagi, Simon
Kaley, Thomas
Melear, Jason
Peereboom, David
Rodriguez, Analiz
Yankelevich, Maxim
Nair, Suresh
Puduvalli, Vinay
Aldape, Kenneth
Gao, Andrew
Lopez-Janeiro, Alvaro
de Andrea, Carlos
Alonso, Marta
Boutros, Paul
Robbins, Joan
Mason, Warren
Sonaben, Adam
Stupp, Roger
Fueyo-Margareto, Juan
Gomez-Manzano, Candelaria
Lang, Frederick
Zadeh, Gelareh
NEURO-ONCOLOGY, 2023, 25
[45] A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.
Mohamadpour, Maliheh
Sherman, Eric Jeffrey
Kriplani, Anuja
Fetten, James Vincent
Dunn, Lara
Michel, Loren S.
Hung, Kin Wai
Baxi, Shrujal S.
McDonald, Erin
Conybeare, Rachel
Katabi, Nora
Ostrovnaya, Irina
Pfister, David G.
Ho, Alan Loh
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[46] Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study
Fuereder, Thorsten
Minichsdorfer, Christoph
Mittlboeck, Martina
Wagner, Christina
Heller, Gerwin
Putz, Eva M.
Oberndorfer, Felicitas
Mullauer, Leonhard
Aretin, Marie-Bernadette
Czerny, Christian
Schwarz-Nemec, Ursula
ORAL ONCOLOGY, 2022, 124
[47] PHASE II TRIAL OF TEMOZOLOMIDE AND TRC 102, BASE EXCISION REPAIR INHIBITOR, IN BEVACIZUMAB NAIVE GLIOBLASTOMA AT FIRST RECURRENCE
Ahluwalia, Manmeet
Drappatz, Jan
Ye, Xiaobu
Walbert, Tobias
Holdhoff, Matthias
Lesser, Glenn
Cloughesy, Tim
Peereboom, David
Nabors, L. Burt
Wen, Patrick
Grossman, Stuart
Rogers, Lisa
NEURO-ONCOLOGY, 2018, 20 : 15 - 15
[48] Final analysis of 2-THE-TOP: A phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma
Tran, David D.
Ghiaseddin, Ashley Parham
Chen, Dongjiang D.
Le, Son B.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[49] A multicenter, randomized controlled phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE).
Ahluwalia, Manmeet Singh
Ciesielski, Michael J.
Reardon, David A.
Butowski, Nicholas A.
Aiken, Robert
Venur, Vyshak
Abad, Ajay Prakash
Mechtler, Laszlo
Peereboom, David M.
Odia, Yazmin
Sinicrope, Kaylyn
Boockvar, John A.
Brenner, Andrew J.
Barbaro, Marissa
Ozair, Ahmad
Belal, Ahmed
Qiu, Jing-Xin
Khosla, Atulya Aman
Casucci, Danielle M.
Fenstermaker, Robert Alan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[50] UPDATES FOR A PHASE 2 OPEN-LABELED STUDY OF PEMBROLIZUMAB PLUS TTFIELDS PLUS MAINTENANCE TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2-THE-TOP)
Ghiaseddin, Ashley
Warren, Sonisha
Allen, Annie
Sampson, Deborah
Chen, Dongjiang
Sherman, Alexandra
Greene, Valerie
Rahman, Maryam
Tran, David
NEURO-ONCOLOGY, 2020, 22 : 33 - 33

← 1 2 3 4 5 →